<PAGE>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549
                                 FORM 10-QSB
  
  (Mark One)
  X     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF
        THE SECURITIES EXCHANGE ACT OF 1934
        For the quarterly period ended December 31, 1997                   
  
        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
        OF THE SECURITIES EXCHANGE ACT OF 1934
        For the transition period from          to                  
  
  Commission file number:  0-16286                       
  
                             MEDPLUS CORPORATION                     
          (Exact name of registrant as specified in its charter)
  
          Delaware                                95-4082020          
  (State or other jurisdiction of     (IRS Employer identification number)
   incorporation or organization)
  
  8 S. Nevada Ave., Ste. 204, Colorado Springs, Colorado      80903   
       (address of principle executive offices)             (Zip Code)
  
                                   719-575-0044                            
             (Registrant's telephone number, including area code)
  
  Indicate by check mark whether the registrant (1) has filed
  all reports required to be filed by section 13 or 15 (d) of
  the Securities Exchange Act of 1934 during the preceding 12
  months (or for such shorter period that the registrant was
  required to file such reports), and (2) has been subject to
  such filing requirements for the past 90 days.  Yes  X   No               
                                                      ---     ---
                       APPLICABLE ONLY TO ISSUERS INVOLVED
                        IN BANKRUPTCY PROCEEDINGS DURING
                            THE PRECEDING FIVE YEARS
                                
  Indicate by check mark whether the registrant has filed all
  documents and reports required to be filed by section 13 or
  15 (d) of the Securities Exchange Act of 1934 subsequent to
  the distribution requirements under a plan confirmed by a
  court.   Yes      No      
               ---     ---
                      APPLICABLE ONLY TO CORPORATE ISSUERS
                              
  Indicate the number of shares outstanding of each of the
  issuer's classes of common stock, as of the latest practicable date.

                 Class                  Outstanding at February 19, 1998
                 -----                  --------------------------------
  Common Stock, Par-Value $.001 per share         10,272,954 
<PAGE>
                             
                             MEDPLUS CORPORATION
                               
                            REPORT ON FORM 10-QSB
                               
                               
                              TABLE OF CONTENTS
                                
  
  PART I                                         PAGE NUMBER
                                                 -----------
  ITEM 1.- FINANCIAL INFORMATION
  
         Balance Sheets at December 31, 1997 . . . . .3
  
         Statements of Operations for the
         Three Months Ended December 31, 1997 
         and December 31, 1996 . . . . . . . . . . . .5
  
         Statements of Cash Flows for the 
         Three Months Ended December 31, 1997
         and December 31, 1996 . . . . . . . . . . . .6
  
         Notes to Financial Statements . . . . . . . .7
  
  ITEM 2.- MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE
         FINANCIAL CONDITION AND RESULTS OF
         OPERATIONS. . . . . . . . . . . . . . .  . . 10
  
  PART II
  
         Other Information . . . . . . . . . . .  . . 11
  
         Signature Page. . . . . . . . . . . . .  . . 12
  
  
  
 <PAGE>
 
                                  PART I
                     ITEM 1.  FINANCIAL INFORMATION
                           MEDPLUS CORPORATION
  
                        CONSOLIDATED BALANCE SHEETS
  
                                              
  ASSETS
                                  December 31, 1997
                                     (Unaudited)
                                  -----------------
  CURRENT ASSETS:
  
  Cash and cash equivalents                2,618
  Accounts receivable                     53,629   
  Prepaid expenses and other
      current assets                       5,428   
  Inventory                                3,172   
  Note receivable from Shareholder        15,000   
                                         -------
  Total current assets                    79,847   
  
  PROPERTY:
  Office Equipment                        41,729
  Furniture and Fixtures                  26,365
  Leasehold Improvements                  87,785   
                                         -------
  Total                                  155,879   
  
  Less accumulated depreciation          (51,545)  
                                         -------  
  Net Property                           104,334   
                                         =======
  TOTAL ASSETS                           184,181   
  
          
                                             
   
                See accompanying notes to financial statements
  
<PAGE>
                             MEDPLUS CORPORATION
                               
                    CONSOLIDATED BALANCE SHEETS  (Continued)
          
                                                December 31, 1997
  LIABILITIES AND SHAREHOLDERS' EQUITY              (Unaudited)
     
  CURRENT LIABILITIES:
     
  Accounts payable and accrued expenses           1,068,035 
  Notes payable to related parties (Note 4)         370,542 
  Deferred Salaries                                  89,075 
  Convertible note payable - net of
        discount (Note 4)                            37,500 
  Notes payable                                     298,411 
  Line of credit                                      5,053 
                                                  ---------
  Total liabilities                               1,868,616 
          
  SHAREHOLDERS' EQUITY:
     
  Preferred stock, $.001 par value;
      authorized 2,000,000 shares;
      no shares outstanding
  Common stock, $.001 par value;
      authorized, 30,000,000 shares;
      issued and outstanding, 3,690,907
      and 8,711,364 shares at March 31, 1997
      and December 31, 1997 respectively              8,322 
  Additional paid in capital                      7,635,558 
  Accumulated deficit                            (9,328,315)
  Net shareholders' equity                       (1,684,435)
                                                  
  TOTAL                                             184,181      
                                                  =========
 
            See accompanying notes to financial statements
    <PAGE>
  
                            MEDPLUS CORPORATION
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                                (UNAUDITED)
                                
                                Three Month Period  Nine Month Period
                                 Ended December 31,  Ended December 31,
                                  1997    1996        1997     1996
                                  ----    ----        ----     ----
  
  PATIENT FINANCE REVENUES:    2,210         0      9,272     55,521
  EXPENSES:                        
  General and Administrative  88,401    96,806    284,350    318,373
  Sales and Marketing         51,507    68,832    244,805    262,602

  Total expenses             139,908   165,638    529,155    580,975
  
  Loss from Operations      (137,698) (165,638)  (519,883)  (525,454)
  
  Loss from Continuing
    Operations              (137,698) (165,638)  (519,883)  (525,454)
  Loss from Discontinued
    Operations of
    Occupational
    Health Clinic            (45,691)  (71,586)  (111,255)  (142,880)
                            --------  --------   --------   --------   
  Operating Loss            (183,389) (237,224)  (631,138)  (668,334)
  
  Total Other Income               0         8          0     90,041
  
  Net loss                  (183,389) (237,216)  (631,138)  (578,293)
  

  Loss Per Share From
    Continuing Operations      (0.02)    (0.01)     (0.07)     (0.06)
  From Discontinued Operations (0.01)    (0.01)     (0.02)     (0.01)
                            --------  --------   --------    -------
  Total                        (0.03)    (0.02)     (0.09)     (0.07)
                            ========  ========   ========    =======

  Weighted average number
    of common shares
    outstanding            7,917,697 9,807,078  7,182,320  8,856,953

                    See accompanying financial statements
<PAGE>
  

                             MEDPLUS CORPORATION
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (UNAUDITED)
  
  
                                          NINE MONTH PERIOD ENDED
                                               December 31,
                                           1997            1996
                                           ----            ----
  CASH FLOWS (USED BY) OPERATING
  ACTIVITIES:

  Net loss                              (631,138)       (578,293)
  
  Adjustments to reconcile net income
  (loss) to net cash from (used)
  by operating activities:
    Depreciation and amortization         17,500          17,180
  (Increase) decrease in assets:        
    Accounts receivable                  (28,759)         (2,105)
  Inventory                               (3,172)         (3,804)
  
  Prepaid expenses and other current
            assets                         9,423          (5,058)
  
  Increase (decrease) in liabilities:
    Accounts payable and accrued
    expenses                             221,566         306,229
                                        --------        -------- 
  Total cash provided (used) by
  operating activities                  (414,580)       (265,851)
  

  CASH FLOWS FROM (USED BY) INVESTING
  ACTIVITIES:
  
  Investment in property, plant and
  equipment                                (101)        (139,172)
  
  Proceeds from sale of equipment             0                0
 
  Additions to property, plant and
    equipment                                 0                0
                                        -------         --------  
  Total cash provided (used) by
    investing activities                   (101)        (139,172)
  

  CASH FLOWS FROM (USED BY) FINANCING
  ACTIVITIES:
  
  Purchase of short term debt           239,382          163,768
  
  Purchase of long term debt                  0           85,000
  
  Payment on short term debt                  0           (5,928)
  
  Payment of note payable                     0                0
  
  Issuance of common stock              175,997          162,081
                                        -------         --------
  Total cash from (used by) financing
    activities                          415,379          404,921
  
  Increase (decrease) in cash and cash
    equivalents                             698             (102)
                                        -------         --------  
  Cash and cash equivalents at beginning
    of period                             1,920            7,778
  
  Cash and cash equivalents at end of
    period                                2,618            7,676
                                        =======         ========  
                                                  
  <PAGE>
                             
                             MEDPLUS CORPORATION
                               
                   NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
                                
  1. BASIS OF PRESENTATION
  
       The accompanying unaudited consolidated financial
       statements of MEDPLUS CORPORATIONcontain all
       adjustments (consisting of only normal recurring
       adjustments) which, in the opinionof management are
       necessary to present fairly the financial position
       of the Company as of theperiods ended December 31,
       1997 and March 31, 1997, and the results of
       operations and its cash flows for the nine month
       periods ended December 31, 1997 and December 31,
       1996. Certain information and footnote disclosures
       normally included in financial statements have been
       condensed or omitted pursuant to rules and
       regulations of the Securities and Exchange
       Commission, although the Registrant believes that
       the disclosures in the consolidated financial
       statements are adequate to make the information
       presented not misleading.
  
       Income Taxes - As of March 31, 1997 the Company has net
       operating loss carryforwards of  approximately $2,362,000,
       which can be utilized in future periods to offset future
       taxable income.   The net operating loss carryforwards
       begin expiring in the year 2000. Due to the Company's net
       operating loss position and carryforwards the adoption
       of SFAS 109 has no material impact.
     
       Operating results for the nine months ended December 31,
       1997 are not necessarily indicative of the results for
       the year ending March 31, 1998
       
       The unaudited consolidated financial statements
       included herein should be read in conjunction
       with the consolidated financial statements of the
       Company for the year ended March 31, 1997,
       included in the Company's Annual Report on Form 10-K.
  
  
  2. COMPUTATION OF NET LOSS PER SHARE
  
       Net loss per share is computed by dividing net loss by
       the weighted average number of shares of common stock
       outstanding. Options and warrants are not included because
       their effect would be antidilutive.
  
  
  3. GOING CONCERN
  
       The accompanying unaudited consolidated financial statements
       have been prepared on a going concern basis, which
       contemplates the realization of assets and the
       satisfaction of liabilities in the normal course of
       business. As reflected in the Company's most recent 10-K
       for the fiscal year ended March 31, 1997, the Company
       has incurred significant losses from operations during
       the years ended March 31, 1997 and 1996 and at March
       31, 1997 and 1996 have negative working capital and
       negative shareholders' equity. The consolidated
       financial statements do not include any adjustments
       relating to the recoverability and classification of
       recorded asset amounts or the amounts and
       classification of liabilities that might be necessary 
       should the Company  be unable to continue as a going
       concern. The Company's continuation as a going concern
       is dependent upon its ability to generate sufficient
       cash to meet its obligations on a timely basis, to obtain
       financing as may be required, and ultimately to attain
       successful operations.  Management is continuing its efforts
       to obtain additional funds needed for the successful operation of
       the Company.  See Item 2. Management's Discussion and
       Analysis of Financial Condition and Results of
       Operations to review management's current success at
       solving the cash flow needs of the Company. 
       
  
  4. NOTES PAYABLE TO RELATED PARTIES
  
       Notes payable to related parties all of which are
       considered to be current liabilities by their term or
       due to default consists of the following at December
       31, 1997 and March 31, 1997:
  
                                   December 31, 1997   March 31, 1997
                                        Unaudited 
                                   -----------------   --------------
  Unsecured note payable to
    Company director bearing 
    interest at 10% per
    annum, $10,000 together 
    with accrued interest and
    $15,000 together with accrued
    interest.                            25,000            25,000
  
  
  Unsecured note payable to a
    former officer and 
    director  of the
    Company bearing interest at 
    18% per annum. The
    note is past due and is 
    currently under dispute.             40,500            40,500
  

 Unsecured note payable to a
   shareholder and former officer of the
   Company, non-interest bearing, 
   due in equal monthly installments
   of $2,000 from May 1996
   through April 1997 with a 
   final installment of $123,288
   payable in May 1997. This note is
   recorded net of unamortized
   discount of  $5,074 at March
   31, 1997 to reflect an
   effective interest rate of 
   18%.  Payments on
   this note are in default.            157,763           157,763
  
  
  Unsecured note payable to
    shareholders of the Company  bearing
    interest at 10% per annum. 
    The note is payable on demand.      106,129           103,962
  
  
  Unsecured note payable to
    shareholder of the Company  bearing
    interest at  11% per annum.
    The note is payable on demand.            0            12,500
  
  
  Unsecured note payable to
    shareholder of the
    Company bearing 
    interest at a range between
    10% and 17%,
    depending on shareholder's 
    credit card rate. 
    The note is payable on demand.      41,150             19,000
  
  
  Total                               $370,542           $358,725
                                      --------           --------    
                                                    
  CONVERTIBLE NOTES PAYABLE
  
  During 1996, the Company issued $100,000 of convertible
  notes due October 1, 2006 bearing interest at 8% per annum. 
  Upon closing of an anticipated public offering of common
  stock, the noteholders have thirty days to convert the notes
  into shares of common stock of the Company in face value
  amount equal to 200% of the dollar amount of the notes based
  on the per share price of the common stock as set forth in
  the anticipated public offering.  In the event the planned
  public offering has not become effective by October 1, 1997,
  the noteholders may, at their sole option, elect to convert
  the notes and all accrued interest into share of common
  stock of the Company based on the closing price per share at
  the close of business on the last business day of the month
  in which the notice is received by the transfer agent. 
  Payments of accrued interest are payable on April 1 and
  October 1.  The Company is in default on the interest
  payments as of February 19, 1988.
  
  In order to recognize the beneficial conversion feature to
  the noteholders of these convertible notes, the Company has
  recorded the $100,000 excess value of the common stock to be
  issued upon the anticipated conversion of the notes over the
  face value as a note discount and additional paid-in
  capital.  The discount is being amortized to interest
  expense from the issuance date through October 1, 1997.
  
  During the year ended March 31, 1997, $50,000 of the
  convertible notes were converted into 256,410 shares of
  common stock.  At the date of conversion, $50,000 of
  unamortized discount was charged to interest expense with a
  corresponding increase to common stock and additional paid-in capital.
  
  NOTES PAYABLE 
         
  Notes payable, all of which are current liabilities by their
  terms, consist of the following:
         
                               December 31, 1997       March 31, 1997
                                  Unaudited              
                               -----------------       --------------
        
  Unsecured note payable to an
    individual bearing 
    interest at 12%,
    interest payable monthly and
    due August 1997                    49,072                49,072
  
  
  Note secured by officers'
    personal stock payable to 
    individuals bearing
    interest at 18% interest and
    principle due August 1998.  
    On November 1, 1997 a note
    holder agreed to convert the
    accrued interest of $3,938
    and principle of $87,500 for
    250,000 shares of common
    stock.  The transaction is                                    
    pending.                          196,108                     0
  
  
  Unsecured note payable to an
    individual bearing 
    interest at 12%,
    interest payable monthly and
    due August 1997.  On November
    1, 1997 the note holder
    agreed to convert the accrued
    interest of $1,500 and
    principle of $25,000 for
    100,000 shares of common
    stock.  The transaction is
    pending.                          25,000                      0
  
  
  Note payable to bank bearing
    interest at 9.875%,  
    collateralized by
    certain assets of a shareholder
    and due June 1997.                28,231                 35,000
  
  
  Unsecured $5,000 line of credit
    bearing interest at 15%.           5,053                  4,327
  
  
  Total                             $303,464                $88,399
                                    --------                -------  
                               
 <PAGE>
                              
               ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                                
  
  LIQUIDITY AND CAPITAL RESOURCES
  
  At December 31, 1997 the Company had working capital of
  ($1,788,769) compared to working capital of ($1,351,027) at
  March 31, 1997.  The decline in working capital is primarily
  due to the Company's net loss for the nine months ended
  December 31, 1997.  The Company's current liabilities are
  higher than its assets due primarily to borrowings in the
  form of promissory notes from shareholders of the Company
  and related parties along with accrued payables and
  expenses.
  
  Liquidity needs are currently being met from revenues,
  short-term borrowing in the form of promissory notes and
  equity financing without which the Company's liquidity
  position would be severely strained.  Because the Company
  has not achieved positive cash flow from its operating
  activities, the Company's ability to continue operations is
  dependent upon its ability to raise additional equity and/or
  debt financing.  As a subsequent event to the period ending
  December 31, 1997, the Company was able to consummate a
  private equity financing with RJC Investments LTD., a
  private investor, which closed on February 6, 1998.  In the
  transaction, RJC invested $250,000 to purchase 1,470,588
  shares of the Company's common stock.  The securities were
  issued relying upon the exemption from securities
  registration afforded by Rule 506 under Regulation D and/or
  Rule 4(2) as promulgated by the United States Securities and
  Exchange Commission under the Securities Act of 1933, as
  amended.  The Agreement with RJC calls for an additional
  investment  of $250,000 on or before April 6, 1998 to
  acquire the same number of shares outlined above and a
  Warrant to purchase 1,250,000 shares of common stock for an
  investment of $500,000.  Although the Company is actively
  engaged in activities with intent to raise equity and/or
  debt financing in order to meet its long-term liquidity
  needs and currently has agreements in place for additional
  equity financing, there can be no assurance that the Company
  will be able to consummate the transaction and/or raise the
  additional financing necessary for continuing operations. 
  As of December 31, 1997, there were no known demands,
  commitment or uncertainties affecting cash flows other than
  normal accounts payable demands, debt, and past due interest
  payments.
  
  RESULTS OF OPERATIONS
  
  Revenue derived from the sale of products from the Company's
  continuing operations was $9,272 for the nine month period
  ended December 31, 1997 as compared to $55,521 in operating
  revenue for the nine month period ended December 31, 1996.
  The Company's revenue decrease over the nine month period
  ended December 31, 1996 is primarily attributable to
  nonpayment of the Company's revenue from United States Bank
  of Oregon and commencing a new relationship with Pullman
  Bank of Chicago, which has limited financial potential.  The
  Company's loan volumes generated to United States Bank of
  Oregon had increased. However, the Company has failed to
  receive any of its revenue from the United States Bank of
  Oregon.  Revenue derived from discontinued operations was
  $208,540 for the nine month period ended December 31, 1997,
  as compared to $19,112 for the nine month period December
  31, 1996.
  
  General and administrative expenses  from continued
  operations decreased 11% from $318,373 during the nine month
  period ended December 31, 1996 to $284,350 during the nine
  month period ended December 31, 1997. The decrease of 11%
  during the nine month period ended December 31, 1997 is due
  primarily to a reduction in support personnel.
  
  Sales and marketing expenses for continued operations
  decreased 7% from $262,602 during the nine month period
  ended December 31, 1996 to $244,805 during the nine month
  period ended December 31, 1997.  The decrease of 7% during
  the nine month period ended December 31, 1997 is primarily
  due to a reduction in sales and marketing personnel.
  
<PAGE>
                               
                               
                                  PART II
                             OTHER INFORMATION
                      
  ITEM 1. LEGAL PROCEEDINGS
  
  See Form 10-KSB regarding litigation.  There were no
  changes for period ending December 31, 1997
       
  ITEM 2. CHANGES IN SECURITIES
  
  None
  
  ITEM 3. DEFAULTS UPON SENIOR SECURITIES
  
  None
  
  ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITIES
          HOLDERS
  
  None
  
  ITEM 5. OTHER INFORMATION
  
  On or about December 23, 1997, the Company received a
  commitment of up to $20 million to purchase health care
  receivables through Capstone and Company, LLC a New
  York based merchant banking company.  The capital will
  be contributed for the purchase of qualified
  receivables generated by the Company's approved health
  care providers at an amount of up to $5,000,000 per
  calendar quarter.  There can be no assurance that this
  commitment will lead to a definitive operating line for
  the Company.
       
  ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
  
     a.  Exhibits
           None
  
     b.  Reports on Form 8-k
           None
    
                               
  <PAGE>
                         
                               
                                
                                  Signatures
  
  Pursuant to the requirements of the Securities and Exchange
  Act of 1934, the registrant has duly caused this report to
  be signed on its behalf by the undersigned thereunto duly
  authorized.
  
  
                                        MEDPLUS CORPORATION
  
  
Date:  February 23, 1998            By:\s\Tim C. DeHerrera
                                        -----------------------
                                        Tim C. DeHerrera
                                        Chief Executive Officer